Pineocytoma
Symptoms, Doctors, Treatments, Advances & More

Learn About Pineocytoma

What is the definition of Pineocytoma?
A Pineocytoma is a tumor of the pineal gland, a small organ in the brain that makes melatonin (a sleep-regulating hormone). Signs and symptoms of Pineocytomas include headaches, nausea, hydrocephalus, vision abnormalities, and Parinaud syndrome. Pineocytomas are usually slow-growing and rarely spread to other parts of the body.
What are the alternative names for Pineocytoma?
  • Pineocytoma
  • Pinealocytoma
  • Pinealoma
Who are the top Pineocytoma Local Doctors?
Elite in Pineocytoma
Radiation Oncology
Elite in Pineocytoma
Radiation Oncology

Adult Neurofibromatosis Type 1 (NF1) And Schwannomatosis Clinic

400 Parnassus Ave., Eighth Floor, 
San Francisco, CA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Dr. David Raleigh is a radiation oncologist who specializes in brain tumors. He cares for both adult and pediatric patients. Raleigh's research focuses on understanding the biological processes that cause brain tumors to grow. His goals are to uncover new measures of brain cancer and to identify cells for drugs to target. Raleigh earned a bachelor's degree in molecular and cell biology as well as a bachelor's degree in cognitive science from the University of California, Berkeley. He earned his doctoral degree in molecular pathogenesis – how disease develops at the molecular level – from the University of Chicago, followed by his medical degree from the Pritzker School of Medicine at the University of Chicago. He completed a residency in radiation oncology at UCSF. Raleigh is a member of the American Society of Clinical Oncology, American Society for Radiation Oncology, Pacific Pediatric Neuro-Oncology Consortium, Children's Oncology Group, Society for Neuro-Oncology, International Meningioma Society and North American Skull Base Society. At the UCSF Brain Tumor Center, Raleigh is a principal investigator with the Wolfe Meningioma Program Project. Dr. Raleigh is rated as an Elite provider by MediFind in the treatment of Pineocytoma. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Meningioma, Pineocytoma, Brain Tumor, and Gliomatosis Cerebri. Dr. Raleigh is board certified in American Board Of Radiology, Radiation Oncology. Dr. Raleigh is currently accepting new patients.

Elite in Pineocytoma
Elite in Pineocytoma
Helsinki, FI 

Joham Velasquez-Choque practices practicing medicine in Helsinki, Finland. Velasquez-Choque is rated as an Elite expert by MediFind in the treatment of Pineocytoma. They are also highly rated in 14 other conditions, according to our data. Their clinical expertise encompasses Pineocytoma, Vein of Galen Aneurysm, Rathke Cleft Cyst, Nerve Decompression, and Extracranial-Intracranial Bypass Surgery.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Pineocytoma
Elite in Pineocytoma

Hospices Civils De Lyon

Bron, FR 

Alexandre Vasiljevic practices practicing medicine in Bron, France. Mr. Vasiljevic is rated as an Elite expert by MediFind in the treatment of Pineocytoma. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Pineocytoma, Pituitary Tumor, Hypothalamic Tumor, and Brain Tumor.

What are the latest Pineocytoma Clinical Trials?
Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Summary: This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor resection cavity or ventricular system in children and young adults with diffuse intrinsic pontine glioma (DIPG), ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

Summary: This is an open-label phase 1 safety and feasibility study that will employ multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) derived from a patient's primary brain tumor tissues. Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due ...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center